The Tumor-to-Endothelial Transfer of FTO Promotes Vascular Remodeling and Metastasis in Nasopharyngeal Carcinoma.

阅读:4
作者:Wu Chun, Liu Xuefei, Gu Liwen, Lian Jingru, Wang Yuting, Cheng Yixin, Duan Lianhui, Huang Guanyin, Chen Siqi, Zhao Boxi, Liu Sailan, Yang Yufan, Zheng Shuqian, Lu Zijian, Guo Wanping, Hu Jianyang, Wang Wenjing, Zuo Zhixiang, Mai Haiqiang, Tang LinQuan, Zhang Songfa, Wen Feiqiu, Hong Xin, Guo Ling
Cancer stem-like cells (CSCs) in nasopharyngeal carcinoma (NPC) exhibit heightened stemness, invasiveness, and resistance to therapy, posing significant challenges for diagnosis and treatment. How CSCs interact with the endothelium to drive vascular remodeling and metastasis remains unclear. Using spatially resolved multi-omic profiling of clinical NPC samples and experimental validation, a tumor-endothelial crosstalk mechanism is identified, driven by the NOTCH1-FTO-SPARC axis. Omics analysis reveals a distinct NOTCH1⁺ CSC subpopulation with enhanced tumorigenic potential. FTO, a direct transcriptional target and key effector of NOTCH1, promotes vascular remodeling and metastasis. Notably, NOTCH1⁺ tumors secreted FTO via exosomes, which are readily taken up by endothelial cells. Within recipient endothelial cells, accumulated FTO disrupts endothelial tight junctions by suppressing YTHDF2-mediated m6A modification, stabilizing SPARC mRNA, and increasing SPARC protein levels. Inhibition of FTO with DAC51 significantly suppresses metastasis in NPC mouse models. Clinically, metastatic NPC patients show elevated levels of NOTCH1⁺ CSC-CTCs (EPCAM⁺ EBNA1⁺ NOTCH1⁺ CD45(-)) and plasma FTO, suggesting their potential as blood-based biomarkers for monitoring disease progression and treatment response. Overall, this study uncovers a non-cell-autonomous role of FTO in driving metastasis, with potential diagnostic and therapeutic utilities for NPC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。